A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience

Basit Öğe Kaydı
dc.authorid0000-0002-7798-4349
dc.authorid0000-0001-8646-1673
dc.authorid0000-0002-3467-8819
dc.authorid0000-0002-6230-9519
dc.authorid0000-0001-9178-2850
dc.authorid0000-0002-7417-2118
dc.authorid0000-0001-6621-3138
dc.authorscopusid36605786600
dc.authorscopusid13205770000
dc.authorscopusid8398092900
dc.authorscopusid56985814600
dc.authorscopusid6504131968
dc.authorscopusid6603145040
dc.authorscopusid55255637200
dc.authorwosidcömert, melda/ABH-5764-2020
dc.authorwosidSaydam, Guray/W-3827-2017
dc.authorwosidsonmez, mehmet/AAL-6243-2021
dc.authorwosidSahin, Handan Haydaroglu/AAH-1389-2020
dc.authorwosidUlu, Bahar Uncu/AAA-3636-2020
dc.authorwosidBilgir, Oktay/G-4445-2014
dc.authorwosidŞencan, Mehmet/AAA-9163-2022
dc.contributor.authorÇekdemir, Demet
dc.contributor.authorGüvenç, Serkan
dc.contributor.authorÖzdemirkıran, Füsun
dc.contributor.authorEser, Ali
dc.contributor.authorTopts, Tayfur
dc.contributor.authorÖzkocaman, Vildan
dc.contributor.authorKüçükkaya, Reyhan Diz
dc.contributor.authorTekinalp, Atakan
dc.contributor.authorTurgut, Burhan
dc.date.accessioned2022-05-11T14:39:57Z
dc.date.available2022-05-11T14:39:57Z
dc.date.issued2019
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractObjective: The aim of the present study was to evaluate the efficacy and safety of eltrombopag, an oral thrombopoietin receptor agonist, in patients with chronic immune thrombocytopenia (ITP). Materials and Methods: A total of 285 chronic ITP patients (187 women, 65.6 %; 98 men, 34.4%) followed in 55 centers were enrolled in this retrospective cohort. Response to treatment was assessed according to platelet count (/mm(3)) and defined as complete (platelet count of >100,000/mm(3)), partial (30,000-100,000/mm(3) or doubling of platelet count after treatment), or unresponsive (<30,000/mm(3)). Clinical findings, descriptive features, response to treatment, and side effects were recorded. Correlations between descriptive, clinical, and hematological parameters were analyzed. Results: The median age at diagnosis was 43.9 +/- 20.6 (range: 3-95) years and the duration of follow-up was 18.0 +/- 6.4 (range: 6-28.2) months. Overall response rate was 86.7% (n=247). Complete and partial responses were observed in 182 (63.8%) and 65 (22.8%) patients, respectively. Thirty-eight patients (13.4%) did not respond to eltrombopag treatment. For patients above 60 years old (n=68), overall response rate was 89.7% (n=61), and for those above 80 years old (n=12), overall response rate was 83% (n=10). Considering thrombocyte count before treatment, eltrombopag significantly increased platelet count at the 1st, 2nd, 3rd, 4th, and 8th weeks of treatment. As the time required for partial or complete response increased, response to treatment was significantly reduced. The time to reach the maximum platelet levels after treatment was quite variable (1-202 weeks). Notably, the higher the maximum platelet count after eltrombopag treatment, the more likely that side effects would occur. The most common side effects were headache (21.6%), weakness (13.7%), hepatotoxicity (11.8%), and thrombosis (5.9%). Conclusion: Results of the current study imply that eltrombopag is an effective therapeutic option even in elderly patients with chronic ITP. However, patients must be closely monitored for response and side effects during treatment. Since both response and side effects may be variable throughout the follow-up period, patients should be evaluated dynamically, especially in terms of thrombotic risk factors.
dc.identifier.doi10.4274/tjh.galenos.2019.2018.0307
dc.identifier.endpage237
dc.identifier.issn1300-7777
dc.identifier.issn1308-5263
dc.identifier.issue4en_US
dc.identifier.pmid31327186
dc.identifier.scopus2-s2.0-85075099354
dc.identifier.scopusqualityQ3
dc.identifier.startpage230
dc.identifier.urihttps://doi.org/10.4274/tjh.galenos.2019.2018.0307
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8807
dc.identifier.volume36
dc.identifier.wosWOS:000497303100003
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorTekinalp, Atakan
dc.institutionauthorTurgut, Burhan
dc.language.isoen
dc.publisherGalenos Yayincilik
dc.relation.ispartofTurkish Journal of Hematology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectThrombocytopenia
dc.subjectImmune thrombocytopenic
dc.subjectEltrombopag
dc.subjectLong-Term
dc.subjectPurpura
dc.subjectSafety
dc.subjectAdults
dc.subjectItp
dc.titleA Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience
dc.title.alternativeRefrakter kronik immün trombositopeni tedavisinde eltrombopagın etkinliğine ilişkin çok merkezli bir çalışma: Gerçek yaşam deneyimi]
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
8807.pdf
Boyut:
254.67 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu